Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development.

The patent granted by the USPTO covers the use of biomarkers in determining the efficacy of SPC-15, a targeted prophylactic treatment using ketamine compositions, as a method of treatment for stress-induced affective disorders or stress-induced psychopathology.

Silo’s CEO Eric Weisblum says the patent is “an important addition” to the company’s IP, by …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.